Synonyms: Briumvi® | LFB-R603 | TG-1101 | TGTX-1101 | ublituximab-xiiy
ublituximab is an approved drug (FDA (2022), EMA (2023))
Compound class:
Antibody
Comment: Ublituximab is a novel third-generation anti-CD20 monoclonal antibody, CD20 being the B lymphocyte cell surface glycoprotein encoded by the MS4A1 gene. This chimeric antibody has been glycoengineered (namely, having a low fucose content in its Fc region) to optimise FcγRIIIA (CD16a) binding, to enhance antibody-dependent cell-mediated cytotoxicity [1-2]. It is being investigated for its immunomodulatory potential.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. Ublituximab shows similar specificity and a similar glycosylation pattern to the anti-CD20 mAb EMAB-6 [1]. |
No information available. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT02656303 | An Open-Label Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304 | Phase 2 Interventional | TG Therapeutics, Inc. | ||
NCT03381170 | An Extension of the TG1101-RMS201 Trial | Phase 2 Interventional | TG Therapeutics, Inc. | ||
NCT04130997 | An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis | Phase 3 Interventional | TG Therapeutics, Inc. | ||
NCT04806035 | Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia | Phase 1 Interventional | TG Therapeutics, Inc. | In this study ublituximab is being combined with the anti-CD47/CD19 bispecific monoclonal TG-1801. TG-1801 targets CD47 selectively on CD19 +ve B cells, thus sparing red blood cells and platelets. |